Semaglutide, the active ingredient in popular GLP-1 weight-loss drugs, is linked to substantially lower risks of worsening mental health conditions, according to a major new study.
Published in The Lancet Psychiatry, the research analyzed over 95,000 patients-average age 50.6-with diagnosed depression or anxiety who used antidiabetic medications between 2009 and 2022. Those on semaglutide saw a 42% lower risk of psychiatric deterioration compared to other treatments. Depression risk dropped by 44%, anxiety by 38%, and substance use disorder-related hospitalizations fell by 47%. Self-harm incidents also declined.
Liraglutide, another GLP-1 drug, showed an 18% reduction in mental health deterioration.
Both medications mimic the natural GLP-1 hormone that regulates appetite and blood sugar. Researchers emphasize the findings are observational-causality cannot be confirmed-but they strongly support launching clinical trials to explore mental health benefits.
The link between diabetes, obesity, and mental illness is well-documented: depression is nearly twice as common in adults with diabetes. Severe mental illness further triples diabetes risk due to medication side effects, lifestyle factors, and systemic health inequities.